BRCA1 and ovarian neoplasm: From clinical trial data, it will be interesting to retrospectively determine whether PARPi treatment activates PGF-FLT1 signaling in human ovarian tumor cells (similar to breast cancer models), which, when effectively blocked by cediranib-plus-olaparib, translates to clinical responses independent of BRCA1/2 status.